Abstract
There is increasing interest in the use of an implantable cardioverter defibrillator (ICD) to manage atrial tachyarrhythmias. Although device-based shock therapy is highly effective in terminating persistent atrial tachyarrhythmias, atrial overdrive pacing may also be useful, particularly when this therapy is applied early after the onset of an arrhythmia. A dual-chamber ICD (Medtronic 7250 Jewel AF®) has been studied in 267 patients with drug-refractory symptomatic AF. The patients were enrolled as part of multicenter clinical trial to evaluate the safety and efficacy of the device to manage atrial tachyarrhythmias in the absence of a standard ventricular ICD indication. The device discriminates atrial tachycardia (AT) from atrial fibrillation (AF) based on cycle length and regularity, and employs multiple methods of atrial overdrive pacing as well as shocks to terminate tachyarrhythmia episodes. Patients were followed for an average of 15.8 ± 9.3 months. A majority (63%) of patients presented with a history of persistent AF and 34% presented with a history of paroxysmal AF. The pacing therapies terminated 54% of AT episodes and 27% of AF episodes. In patients with persistent AF, 75% of the AT/AF episodes that were successfully terminated by pacing lasted ≤9 minutes. When the pacing therapies failed, episodes lasted for several hours and 50% of the episodes received at least one shock. The results of this trial suggest that pace-termination plays an important role in device-based management of atrial tachyarrhythmias. It is estimated that early pace-termination of AT/AF episodes may reduce the need for device-based shocks among patients with persistent AF by about half.
Similar content being viewed by others
References
Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852–1923.
Schoels W, Swerdlow CD, Jung W, Stein KM, Seidl K, Haffajee CJ, for the Worldwide Jewel AF Investigators. Worldwide clinical experience with a new dual-chamber implantable cardioverter-defibrillator system. J Cardiovasc Electrophys 2001;12:521–528.
Adler SW II, Wolpert C, Warman EN, Musley SK, Koehler JL, Euler DE. Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator. Circulation 2001;104:887–892.
Friedman PA, Dijkman B, Warman EN, Xia HA, Mehra R, Stanton MS, Hammill SC. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 2001;104:1023–1028.
Dijkman B, Wellens HJ. Diagnosis and therapy of atrial tachyarrhythmias in the dual chamber implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 2000;11:1196–1205.
Gold MR, Sulke N, Schwartzman DS, Mehra R, Euler DE. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol 2001;12:1247–1253.
Swerdlow CD, Schwartzman D, Hoyt R, Bailin SJ, Koehler JL, Warman EN. Determinants of first-shock success for atrial implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 2002;13:347–354.
Schwartzman D, Musley SK, Swerdlow CD, Hoyt RH, Warman EN. Early recurrence of atrial fibrillation following ambulatory shock conversion. J Am Coll Cardiol 2002;40:93–99.
Mitchell AR, Spurrell PA, Cheatle L, Sulke N. Effect of atrial antitachycardia pacing treatments in patients with an atrial defibrillator: Randomised study comparing subthreshold and nominal pacing outputs. Heart 2002;87:433–437.
Swerdlow CD, Schšls W, Dijkman B, Jung W, Sheth NV, Olwon WH, Gunderson BD. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter defibrillator. Circulation 2000;101:878–885.
Newman DM, Dorian P, Paquette M, Sulke N, Gold MR, Schwartzman DS, Schaaf K, Wood K, Johnson L. The effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, healthrelated quality of life. Am Heart J 2002;145:841–846.
Paladino W, Bahu M, Knight BP, Weiss R, Sousa J, Zivin A, Goyal R, Daoud E, K. Ching Man K, Strickberger A, Morady F. Failure of single-and multisite high-frequency atrial pacing to terminate atrial fibrillation. Am J Cardiol 1997;80:226–227.
Giorgberidze I, Saksena S, Mongeon L, Mehra R, Krol RB, >Munsif AN, Mathew P: Effects of high-frequency atrial pacing in atypical atrial flutter and atrial fibrillation. J Interv Cardiac Electrophysiol 1997;1:111–123.
Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gold, M.R., Leman, R.B. & Euler, D.E. Effectiveness of Rapid Atrial Pacing for Termination of Drug Refractory Atrial Fibrillation: Results of a Dual Chamber Implantable Cardioverter Defibrillator Trial. Card Electrophysiol Rev 7, 341–344 (2003). https://doi.org/10.1023/B:CEPR.0000023134.41562.79
Issue Date:
DOI: https://doi.org/10.1023/B:CEPR.0000023134.41562.79